Abstract: Lipidated oxoadenines of formula (I) are TLR7/8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.

Abstract: Disclosed herein are diaryl trehalose compounds and methods of use thereof, for example as vaccine adjuvants.

Abstract: Provided herein are TLR7/8 agonists to enhance immune responses or for use as adjuvants in fentanyl vaccines in opioid-using individuals.

Abstract: Disclosed herein are immunogenic trehalose compounds and methods of use thereof, for example as vaccine adjuvants.

Abstract: The methods and compositions described herein relate to methods of immunization or stimulating an immune response, e.g., using agonists of TLR7 and/or TLR8 as antigens. The methods and compositions described herein have particular relevance to use in infants.

Abstract: This disclosure relates to compounds that target microtubules, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases. More particularly, this disclosure relates to modified carbazole compounds and pharmaceutical compositions thereof, methods of targeting microtubules with these compounds, and methods of treating diseases affected by microtubule disruption.

Abstract: 16-membered macrolide compounds inhibit growth of various microbial species and have utility in the treatment of systemic or topical microbial infections, including methicillin-resistant strains (Formula I).

Abstract: An autonomous bioaerosol sampling and detection system and method adapted to provide real-time detection and identification of bio-organisms in aerosols without human intervention.

Abstract: A compound, or a protonate or salt thereof, of formula I: wherein Y is aryl, substituted aryl, heteroaryl, or substituted heteroaryl; n is 1 or 2; each R10 is independently alkyl, substituted alkyl, a polyether moiety, carboxyl, substituted carboxyl, alkoxy, substituted alkoxy, haloalkyl, halogen, nitro, amino, aryloxy, aryl, substituted aryl, cyano, hydroxyl, carbonylamino, aminocarbonyl, acyl, sulfonyl, or substituted sulfonyl; a is 0 to 4; is an aryl or heteroaryl ring; and each R is independently halogen, carbonylamino, sulfonamide, carboxylic acid or hydrogen, provided at least one R is a halogen; and provided that if Y is are not respectively.

Abstract: The present invention is directed to pharmaceutical compositions and methods of treating traumatic brain injury (TBI). The invention is also directed to pharmaceutical compositions and methods of treating a transient hypoxic and/or ischemic condition in the central nervous system. More specifically, the present invention is directed to pharmaceutical compositions and methods of reducing the occurrence of nerounal cell death in the centeral nervous system, such as, reducing the occurrence brain cell death in the hippocampus and/or the cortex.

Abstract: The present invention is directed to pharmaceutical compositions and methods of treating traumatic brain injury (TBI). The invention is also directed to pharmaceutical compositions and methods of treating a transient hypoxic and/or ischemic condition in the central nervous system. More specifically, the present invention is directed to pharmaceutical compositions and methods of reducing the occurrence of neuronal cell death in the central nervous system, such as, reducing the occurrence brain cell death in the hippocampus and/or the cortex.

Abstract: The present invention provides minimally invasive methods of detecting, diagnosing, and assessing neuronal damage associated with traumatic brain injury (TBI) or chronic traumatic encephalopathy (CTE). Specific species of microRNAs (miRNA), small, noncoding RNA molecules that play gene regulatory functions, are correlated with cellular damage and oxidative stress following TBI or CTE, allowing for rapid, minimally-invasive diagnosis and assessment of brain injury. The early identification and longitudinal assessment of neuronal damage in subjects suffering from or at risk of suffering from a TBI (e.g., football players, boxers, military personnel, fall victims) will improve clinical outcomes by guiding critical medical and behavioral decision making.

Abstract: The methods and compositions described herein relate to methods of immunization or stimulating an immune response, e.g., using agonists of TLR7 and/or TLR8 as antigens. The methods and compositions described herein have particular relevance to use in infants.

Abstract: 16-membered macrolide compounds inhibit growth of various microbial species and have utility in the treatment of systemic or topical microbial infections, including methicillin-resistant strains (Formula I).

Abstract: The present invention provides minimally invasive methods of detecting, diagnosing, and assessing neuronal damage associated with traumatic brain injury (TBI) or chronic traumatic encephalopathy (CTE). Specific species of microRNAs (miRNA), small, noncoding RNA molecules that play gene regulatory functions, are correlated with cellular damage and oxidative stress following TBI or CTE, allowing for rapid, minimally-invasive diagnosis and assessment of brain injury. The early identification and longitudinal assessment of neuronal damage in subjects suffering from or at risk of suffering from a TBI (e.g., football players, boxers, military personnel, fall victims) will improve clinical outcomes by guiding critical medical and behavioral decision making.

Abstract: A compound, or a protonate or salt thereof, of formula I: wherein Y is aryl, substituted aryl, heteroaryl, or substituted heteroaryl; n is 1 or 2; each R10 is independently alkyl, substituted alkyl, a polyether moiety, carboxyl, substituted carboxyl, alkoxy, substituted alkoxy, haloalkyl, halogen, nitro, amino, aryloxy, aryl, substituted aryl, cyano, hydroxyl, carbonylamino, aminocarbonyl, acyl, sulfonyl, or substituted sulfonyl; a is 0 to 4; is an aryl or heteroaryl ring; and each R is independently halogen, carbonylamino, sulfonamide, carboxylic acid or hydrogen, provided at least one R is a halogen; and provided that if Y is are not respectively.

Abstract: The present invention is directed to pharmaceutical compositions and methods of treating traumatic brain injury (TBI). The invention is also directed to pharmaceutical compositions and methods of treating a transient hypoxic and/or ischemic condition in the central nervous system. More specifically, the present invention is directed to pharmaceutical compositions and methods of reducing the occurrence of neuronal cell death in the central nervous system, such as, reducing the occurrence brain cell death in the hippocampus and/or the cortex.

Abstract: The present invention provides T-type calcium channel modulators and methods for producing and using the same. In some embodiments, compounds of the invention are of the formula: where R1 is selected from the group consisting of alkyl, alkenyl, polyether, alkoxy and cycloalkyl; X is selected from the group consisting of methylene, —C(?O)—[NR4]a—, —C(?S)—, and —S(?O)b; R2 is selected from the group consisting of heterocycloalkyl and heteroaryl; R3 is selected from the group consisting of alkyl, alkenyl, polyether, alkoxy, cycloalkyl, —NR5R6, —C(?O)NR5R6, —C(?O)ORa (where Ra is alkyl, typically C1-C8 alkyl, often C2-C6 alkyl, and in one particular embodiment Ra is tert-butyl), and —SO2NR5R6; R4 is hydrogen, alkyl, or a nitrogen protecting group; each of R5 and R6 are independently selected from the group consisting of hydrogen and alkyl; a is 0 or 1; b is 1 or 2; n=1 to 3; and m=0 to 1.

Abstract: The present invention provides minimally invasive methods of detecting, diagnosing, and assessing neuronal damage associated with traumatic brain injury (TBI) or chronic traumatic encephalopathy (CTE). Specific species of microRNAs (miRNA), small, noncoding RNA molecules that play gene regulatory functions, are correlated with cellular damage and oxidative stress following TBI or CTE, allowing for rapid, minimally-invasive diagnosis and assessment of brain injury. The early identification and longitudinal assessment of neuronal damage in subjects suffering from or at risk of suffering from a TBI (e.g., football players, boxers, military personnel, fall victims) will improve clinical outcomes by guiding critical medical and behavioral decision making.

Abstract: The present disclosure is generally directed to compositions and methods for treating diseases that are ameliorated by the inhibition of CYP26 mediated retinoic acid metabolism. The compositions comprise compounds of formula (I).